Compare BridgeBio Pharma Inc (BBIO) vs VanEck Video Gaming and eSports ETF (ESPO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck Video Gaming and eSports ETF — how do they compare? BridgeBio Pharma Inc trades at $84.7 (market cap $16.46B), while VanEck Video Gaming and eSports ETF trades at $91.42. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | ESPO | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $122.30 |
52-Week Low | $44.81 | $85.25 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
ESPO, the VanEck Video Gaming and eSports ETF, trades at $91.78, down 0.62% on the day. Technical indicators show a bullish trend with moving averages signaling strength, though oscillators are neutral and short-term RSI levels suggest overbought conditions. Recent news highlights institutional accumulation and AI-driven profit potential in the gaming sector, with Assetmark Inc. increasing its stake by 35.9% as of its latest 13F filing (SEC, Q1 2026).
The outlook for ESPO is supported by structural growth in digital entertainment and AI efficiency gains, but risks include sector volatility and high valuation multiples. The ETF offers exposure to a high-growth industry, yet investors face concentration risk in gaming stocks and sensitivity to consumer discretionary spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →
